Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 38
Filter
2.
Eur J Nucl Med Mol Imaging ; 48(12): 3925-3939, 2021 11.
Article in English | MEDLINE | ID: mdl-33851243

ABSTRACT

PURPOSE: The objective of this review was to explore the potential clinical application of unconventional non-amino acid PET radiopharmaceuticals in patients with gliomas. METHODS: A comprehensive search strategy was used based on SCOPUS and PubMed databases using the following string: ("perfusion" OR "angiogenesis" OR "hypoxia" OR "neuroinflammation" OR proliferation OR invasiveness) AND ("brain tumor" OR "glioma") AND ("Positron Emission Tomography" OR PET). From all studies published in English, the most relevant articles were selected for this review, evaluating the mostly used PET radiopharmaceuticals in research centers, beyond amino acid radiotracers and 2-[18F]fluoro-2-deoxy-D-glucose ([18F]FDG), for the assessment of different biological features, such as perfusion, angiogenesis, hypoxia, neuroinflammation, cell proliferation, tumor invasiveness, and other biological characteristics in patients with glioma. RESULTS: At present, the use of non-amino acid PET radiopharmaceuticals specifically designed to assess perfusion, angiogenesis, hypoxia, neuroinflammation, cell proliferation, tumor invasiveness, and other biological features in glioma is still limited. CONCLUSION: The use of investigational PET radiopharmaceuticals should be further explored considering their promising potential and studies specifically designed to validate these preliminary findings are needed. In the clinical scenario, advancements in the development of new PET radiopharmaceuticals and new imaging technologies (e.g., PET/MR and the application of the artificial intelligence to medical images) might contribute to improve the clinical translation of these novel radiotracers in the assessment of gliomas.


Subject(s)
Brain Neoplasms , Glioma , Artificial Intelligence , Brain Neoplasms/diagnostic imaging , Fluorodeoxyglucose F18 , Glioma/diagnostic imaging , Humans , Molecular Imaging , Positron-Emission Tomography , Radiopharmaceuticals , Tomography, X-Ray Computed
3.
Cardiovasc Intervent Radiol ; 42(11): 1644-1648, 2019 Nov.
Article in English | MEDLINE | ID: mdl-31218410

ABSTRACT

PURPOSE: The aim of this study is to evaluate the feasibility of percutaneous lung tumor biopsy under cone beam-computed tomography (CBCT) with PET-CT imaging fusion. MATERIALS AND METHODS: Eleven patients (four women and seven men) underwent C-arm CBCT lung biopsy with PET-CT fusion imaging. A preprocedural PET-CT scan was manually fused with procedural CBCT based on anatomical landmarks; using real-time fluoroscopy, the coregistered PET-CT and CBCT images were overlaid to guide the needle trajectory. Technical success, accuracy, sensibility and specificity were evaluated. Mean total procedure time and time required for image elaboration were recorded. RESULTS: Technical success, diagnostic accuracy, sensitivity and specificity were 100%. The mean procedure time was 38 min. The average time of PET-CT/CBCT image fusion elaboration was 3.53 min for planning and 3.42 min for needle positioning check. CONCLUSION: CBCT-guided percutaneous lung biopsy with PET-CT fusion imaging is a feasible and effective procedure, with the potential to further improve diagnostic yield by targeting the most metabolically active portion of a lesion, whether it is morphologically altered or normal.


Subject(s)
Cone-Beam Computed Tomography/methods , Lung Neoplasms/diagnostic imaging , Lung Neoplasms/pathology , Positron Emission Tomography Computed Tomography/methods , Radiography, Interventional/methods , Aged , Aged, 80 and over , Feasibility Studies , Female , Humans , Image-Guided Biopsy/methods , Lung/diagnostic imaging , Lung/pathology , Male , Middle Aged , Prospective Studies , Reproducibility of Results , Sensitivity and Specificity
4.
Med Oncol ; 34(10): 174, 2017 Sep 05.
Article in English | MEDLINE | ID: mdl-28875374

ABSTRACT

The aim of this study was to evaluate the efficacy and the safety of Y90 radioembolization (Y90-RE) in patients with unresectable hepatocellular carcinoma (HCC) analysing our results and correlating them with independent prognostic factors for overall survival (OS) and for complications. Forty-three patients with advanced inoperable HCC including those with multiple bilobar lesions or portal vein thrombosis (PVT) treated with Y90-RE were reviewed. Treatment efficacy and safety were evaluated. Survival was calculated by the Kaplan-Meier method. Univariate analyses were performed for identifying potential prognostic factors. Radiologic response was evaluated with the modified Response Evaluation Criteria in Solid Tumours (mRECIST) criteria. Clinical toxicities were prospectively recorded. Median overall progression-free survival and OS were 27.7 and 16.8 months, respectively. Longer median OS was revealed in those without PVT (p = 0.0241) and those whose pre-treatment haemoglobin values was higher (p = 0.0471). According with mRECIST criteria, we observed a disease control rate of 69.2 and 61.9% at 3- and 6-month follow-up, respectively. Complications developed in 28 patients (65.1%), among which grade 2-3 events were reported in 17 patients. We noted that activity administered dose presented a correlation with intra-procedural toxicity (p = 0.039259) while common hepatic artery use as release site was associated with a most frequent presentation of remote adverse events. Y90-RE is an alternative treatment with a promising outcome for poor-risk advanced inoperable HCC. PVT and pre-treatment haemoglobin values can be predictors of efficacy. Activity administered dose and arterial release site can be predictors of safety.


Subject(s)
Carcinoma, Hepatocellular/therapy , Embolization, Therapeutic/methods , Liver Neoplasms/therapy , Aged , Carcinoma, Hepatocellular/mortality , Disease-Free Survival , Embolization, Therapeutic/adverse effects , Female , Humans , Kaplan-Meier Estimate , Liver Neoplasms/mortality , Male , Middle Aged , Prognosis , Radiopharmaceuticals , Treatment Outcome , Yttrium Radioisotopes
5.
J Nucl Cardiol ; 24(3): 876-887, 2017 06.
Article in English | MEDLINE | ID: mdl-26911365

ABSTRACT

BACKGROUND: The introduction of a camera-based dose-reduction strategy in myocardial perfusion imaging (MPI) clinical setting entails the definition of objective and reproducible criteria for establishing the amount of activity to be injected. AIM: The aim is to evaluate the impact of count statistics on the estimation of summed-scores (SS), end-diastolic volume (EDV), end-systolic volume (ESV), and ejection fraction (EF). METHODS: Data rest/stress ECG-gated SPECT (2-day protocol and 8 MBq·kg-1) were acquired with Bright View gamma camera and Astonish algorithm for 40 normal-weight and 40 overweight patients. Assuming that count statistics of shorter acquisition time may simulate that of lower injected activity, three simultaneous scans (full-time, half-time, and quarter-time scans) were started at the same time but with different acquisition time/projection (30, 15 and 8 seconds). RESULTS: A significant difference between SS values of half-time and quarter-time stress scans was found for overweight group (P = .006). Post hoc test showed significant differences for ESV (P < .05), EDV (P < .01) and EF (P < .05) between half-time and quarter-time scans for both patient groups. CONCLUSIONS: The reduction of the count-statistics to a quarter of the MPI reference influenced negatively the quantification in overweight patients. The decrease of radiopharmaceutical activity to 25% of the reference seems practicable for normal-weight patients, while it is more appropriate an activity reduction limited to 50% for overweight and obese patients.


Subject(s)
Cardiac-Gated Single-Photon Emission Computer-Assisted Tomography/methods , Coronary Artery Disease/diagnostic imaging , Image Interpretation, Computer-Assisted/methods , Obesity/diagnostic imaging , Organophosphorus Compounds/administration & dosage , Organotechnetium Compounds/administration & dosage , Radiation Exposure/analysis , Radiation Exposure/prevention & control , Aged , Female , Humans , Image Enhancement/methods , Male , Myocardial Perfusion Imaging , Radiation Protection/methods , Radiopharmaceuticals/administration & dosage , Reproducibility of Results , Sensitivity and Specificity , Stroke Volume
6.
Clin Transl Imaging ; 4(6): 491-498, 2016.
Article in English | MEDLINE | ID: mdl-27933282

ABSTRACT

PURPOSE: Over the past decade, nuclear medicine experts have been seeking to minimize patient exposure to radiation in myocardial perfusion scintigraphy (MPS). This review describes the latest technological innovations in MPS, particularly with regard to dose reduction. METHODS: We searched in PubMed for original clinical papers in English, published after 2008, using the following research criteria: (dose) and ((reduction) or (reducing)) and ((myocardial) or (cardiac) or (heart)) and ((nuclear medicine) or (nuclear imaging) or (radionuclide) or (scintigraphy) or (SPET) or (SPECT)). Thereafter, recent reviews on the topic were considered and other relevant clinical papers were added to the results. RESULTS: Of 202 non-duplicate articles, 17 were included. To these, another eight papers cited in recent reviews were added. By optimizing the features of software, i.e., through algorithms for iterative reconstruction with resolution recovery (IRRs), and hardware, i.e., scanners and collimators, and by preferring, unless otherwise indicated, the use of stress-first imaging protocols, it has become possible to reduce the effective dose by at least 50% in stress/rest protocols, and by up to 89% in patients undergoing a diagnostic stress-only study with new technology. With today's SPECT/CT systems, the use of a stress-first protocol can conveniently be performed, resulting in an overall dose reduction of about 35% if two-thirds of stress-first examinations were considered definitively normal. CONCLUSION: Using innovative gamma cameras, collimators and software, as well as, unless otherwise indicated, stress-first imaging protocols, it has become possible to reduce significantly the effective dose in a high percentage of patients, even when X-ray CT scanning is performed for attenuation correction.

8.
Funct Neurol ; 31(4): 205-215, 2016.
Article in English | MEDLINE | ID: mdl-28072381

ABSTRACT

Neuroimaging, both with magnetic resonance imaging (MRI) and positron emission tomography (PET), has gained a pivotal role in the diagnosis of primary neurodegenerative diseases. These two techniques are used as biomarkers of both pathology and progression of Alzheimer's disease (AD) and to differentiate AD from other neurodegenerative diseases. MRI is able to identify structural changes including patterns of atrophy characterizing neurodegenerative diseases, and to distinguish these from other causes of cognitive impairment, e.g. infarcts, space-occupying lesions and hydrocephalus. PET is widely used to identify regional patterns of glucose utilization, since distinct patterns of distribution of cerebral glucose metabolism are related to different subtypes of neurodegenerative dementia. The use of PET in mild cognitive impairment, though controversial, is deemed helpful for predicting conversion to dementia and the dementia clinical subtype. Recently, new radiopharmaceuticals for the in vivo imaging of amyloid burden have been licensed and more tracers are being developed for the assessment of tauopathies and inflammatory processes, which may underlie the onset of the amyloid cascade. At present, the cerebral amyloid burden, imaged with PET, may help to exclude the presence of AD as well as forecast its possible onset. Finally PET imaging may be particularly useful in ongoing clinical trials for the development of dementia treatments. In the near future, the use of the above methods, in accordance with specific guidelines, along with the use of effective treatments will likely lead to more timely and successful treatment of neurodegenerative dementias.


Subject(s)
Brain Mapping/methods , Brain/diagnostic imaging , Dementia/diagnostic imaging , Magnetic Resonance Imaging/methods , Neurodegenerative Diseases/diagnostic imaging , Positron-Emission Tomography/methods , Alzheimer Disease/diagnostic imaging , Alzheimer Disease/pathology , Brain/pathology , Brain/physiopathology , Dementia/complications , Dementia/pathology , Humans , Neurodegenerative Diseases/complications , Neurodegenerative Diseases/pathology
9.
Eur J Nucl Med Mol Imaging ; 43(2): 340-348, 2016 Feb.
Article in English | MEDLINE | ID: mdl-26250689

ABSTRACT

PURPOSE: The aim of this study was to analyse if the result of a baseline (18)F-fluorodeoxyglucose (FDG) positron emission tomography (PET)/CT scan, in large-vessel vasculitis (LVV) patients, is able to predict the course of the disease, not only in terms of presence/absence of final complications but also in terms of favourable/complicated progress (response to steroid therapy, time to steroid suspension, relapses, etc.). METHODS: A total of 46 consecutive patients, who underwent (18)F-FDG PET/CT between May 2010 and March 2013 for fever of unknown origin (FUO) or suspected vasculitis (before starting corticosteroid therapy), were enrolled. The diagnosis of LVV was confirmed in 17 patients. Considering follow-up results, positive LVV patients were divided into two groups, one characterized by favourable (nine) and the other by complicated progress (eight), on the basis of presence/absence of vascular complications, presence/absence of at least another positive PET/CT during follow-up and impossibility to comply with the tapering schedule of the steroid due to biochemical/symptomatic relapse. Vessel uptake in subjects of the two groups was compared in terms of intensity and extension. To evaluate the extent of active disease, we introduced two volume-based parameters: "volume of increased uptake" (VIU) and "total lesion glycolysis" (TLG). The threshold used to calculate VIU on vessel walls was obtained by the "vessel to liver" ratio by means of receiver-operating characteristic analysis and was set at 0.92 × liver maximum standardized uptake value in each patient. RESULTS: Measures of tracer uptake intensity were significantly higher in patients with complicated progress compared to those with a favourable one (p < 0.05). Measures of disease extension were even more significant and TLG emerged as the best parameter to separate the two groups of patients (p = 0.01). CONCLUSION: This pilot study shows that, in LVV patients, the combined evaluation of the intensity and the extension of FDG vessel uptake at diagnosis can predict the clinical course of the disease, separating patients with favourable or complicated progress.


Subject(s)
Arteritis/diagnostic imaging , Multimodal Imaging , Positron-Emission Tomography , Tomography, X-Ray Computed , Adrenal Cortex Hormones/administration & dosage , Aged , Arteritis/drug therapy , Arteritis/pathology , Female , Fluorodeoxyglucose F18 , Humans , Male , Middle Aged , Radiopharmaceuticals
10.
HIV Med ; 16(9): 563-71, 2015 Oct.
Article in English | MEDLINE | ID: mdl-25944496

ABSTRACT

OBJECTIVES: The aim of this study was to evaluate the clinical impact of including lateral spine X-ray in the screening of bone diseases in HIV-positive patients. METHODS: A total of 194 HIV-positive patients underwent dual-energy X-ray absorptiometry (DEXA), lateral spine X-ray and bone biochemical analysis. Vertebral fractures were identified using a morphometric analysis of X-rays and classified using the semiquantitative scoring system of Genant et al. For each patient, a spine deformity index (SDI) score was calculated by summing the grades of vertebral deformities. Reductions in vertebral body height of > 25% were considered vertebral fractures, and those < 25% were considered vertebral deformities. Risk factors associated with vertebral fractures were evaluated by univariate and multivariate analysis. RESULTS: Vertebral fractures were detected in 24 patients (12.4%) and vertebral deformities in 17 patients (8.7%); 153 patients (78.9%) did not show any vertebral deformity. Among patients with fractures, only two with SDI > 10 reported lumbar pain; the remaining were asymptomatic. Patients over 50 years old showed a higher prevalence of vertebral fracture [24.4% versus 11.8% in patients 41-50 years old (P = 0.05) and 1.9% in patients ≤ 40 years old (P = 0.04)]. No significant increase in the prevalence according to bone mineral density (BMD) reduction was observed, and 70% of fractures were diagnosed in nonosteoporotic patients. Older age [adjusted odds ratio 1.09; 95% confidence interval (CI) 1.03-1.13; P = 0.001] and steroid use (adjusted odds ratio 3.64; 95% CI 1.29-10.3; P = 0.01) were independently associated with vertebral fracture; no association was found with HIV- or highly active antiretroviral therapy (HAART)-related variables. CONCLUSIONS: A prevalence of vertebral fractures of 12.4% was observed in our HIV-positive cohort. Given that two-thirds of fractures occurred in nonosteoporotic patients, spine X-ray may be considered in patients at increased risk, irrespective of BMD; that is, in elderly patients and/or patients using steroids.


Subject(s)
HIV Infections/complications , Spinal Fractures/diagnostic imaging , Spinal Fractures/epidemiology , Absorptiometry, Photon/methods , Adult , Bone Density , Female , HIV Infections/diagnostic imaging , Humans , Male , Middle Aged , Prevalence , Risk Factors
11.
Clin Transl Oncol ; 16(9): 770-5, 2014 Sep.
Article in English | MEDLINE | ID: mdl-24647843

ABSTRACT

Fluorine-18-fluorodeoxyglucose (F-18-FDG) is the most used positron emitter radiopharmaceutical worldwide. This glucose analogue allows to study the glucose metabolism which is often increased in many tumors. Nowadays the diagnostic performance of positron emission tomography/computed tomography (PET/CT) using F-18-FDG in different tumors is well known. On the other hand, to date, there is an increasing interest for the use of PET tracers other than F-18-FDG in oncology, because they allow to study different metabolic pathways or receptor expression. The aim of this review is to summarize the scientific literature about the diagnostic performance of PET/CT using tracers other than F-18-FDG in oncology through an evidence-based approach. In particular, the results of meta-analyses (representing the highest level of evidence) on the diagnostic performance of PET tracers other than F-18-FDG in different tumors are described. Furthermore, recommendations for the use of different PET tracers in oncology are provided based on existing literature data.


Subject(s)
Medical Oncology/methods , Neoplasms/diagnosis , Positron-Emission Tomography/methods , Radiopharmaceuticals , Tomography, X-Ray Computed/methods , Evidence-Based Medicine , Fluorodeoxyglucose F18 , Humans , Multimodal Imaging/methods , Neoplasms/diagnostic imaging
12.
Q J Nucl Med Mol Imaging ; 54(5): 564-9, 2010 Oct.
Article in English | MEDLINE | ID: mdl-20927024

ABSTRACT

AIM: Several lines of evidence indicate that the dopaminergic system may play a role in the propagation of epileptic seizures and, indeed, DOPA metabolism impairment has recently been demonstrated in PET studies of ring chromosome 20 [r(20)] patients. We conducted a study looking for correlations between r(20) mosaicism, other clinical variables and both pre-synaptic dopamine transporter (DAT) expression and post-synaptic D2 receptor density. METHODS: Five patients with r(20) and epilepsy were enrolled in the study. DAT expression and D2 density were measured by single photon emission tomography (SPECT) imaging with 185 MBq of [¹²³I]ioflupane and [¹²³I]IBZM, respectively, on different days. Linear correlations between r(20) mosaicism, clinical variables and binding of [¹²³I]ioflupane or [¹²³I]IBZM were examined. RESULTS: A significant correlation between seizure frequency and r(20) mosaicism was detected (r=0.903, P<0.05), along with a negative correlation between r(20) mosaicism and binding of [¹²³I]ioflupane in the putamen and in the caudate nucleus (r=-0.692 and r=-807; P<0.05). Seizure frequency was positively correlated with post-synaptic D2 density (r=0.925, P<0.05). CONCLUSION: Striatal neurons are involved in r(20) epilepsy; the relationship found between r(20) mosaicism and DAT expression suggests that drugs acting on the dopaminergic system could have a place in the treatment of this rare form of epilepsy.


Subject(s)
Chromosome Disorders/diagnostic imaging , Chromosome Disorders/metabolism , Dopamine/metabolism , Tomography, Emission-Computed, Single-Photon , Adolescent , Adult , Child , Child, Preschool , Chromosome Disorders/complications , Chromosome Disorders/genetics , Chromosomes, Human, Pair 20/genetics , Dopamine Plasma Membrane Transport Proteins/metabolism , Epilepsy/complications , Female , Humans , Male , Middle Aged , Mosaicism , Ring Chromosomes , Synapses/metabolism , Young Adult
13.
Article in English | MEDLINE | ID: mdl-20585311

ABSTRACT

AIM: Several lines of evidence indicate that the dopaminergic system may play a role in the propagation of epileptic seizures and, indeed, DOPA metabolism impairment has recently been demonstrated in PET studies of ring chromosome 20 [r(20)] patients. We conducted a study looking for correlations between r(20) mosaicism, other clinical variables and both pre-synaptic dopamine transporter (DAT) expression and post-synaptic D2 receptor density. METHODS: Five patients with r(20) and epilepsy were enrolled in the study. DAT expression and D2 density were measured by single photon emission tomography (SPECT) imaging with 185 MBq of [123I]ioflupane and [123I]IBZM, respectively, on different days. Linear correlations between r(20) mosaicism, clinical variables and binding of [123I]ioflupane or [123I]IBZM were examined. RESULTS: A significant correlation between seizure frequency and r(20) mosaicism was detected (r=0.903, P<0.05), along with a negative correlation between r(20) mosaicism and binding of [123I]ioflupane in the putamen and in the caudate nucleus (r=-0.692 and r=-807; P<0.05). Seizure frequency was positively correlated with post-synaptic D2 density (r=0.925, P<0.05). CONCLUSION: Striatal neurons are involved in r(20) epilepsy; the relationship found between r(20) mosaicism and DAT expression suggests that drugs acting on the dopaminergic system could have a place in the treatment of this rare form of epilepsy.

15.
Q J Nucl Med Mol Imaging ; 53(6): 646-57, 2009 Dec.
Article in English | MEDLINE | ID: mdl-20016455

ABSTRACT

AIM: The aim of this study was to assess whether 18F-fluorodeoxyglucose positron emission tomography differentiates amnestic (aMCI) from single-non-amnestic mild cognitive impairment (snaMCI) with executive dysfunction. METHODS: Sixteen aMCI subjects (62% females, age 75+/-8 years) and 14 snaMCI subjects (71% females, age 74+/-6 years) underwent [18F]FDG-PET and clinical follow-up. Comparisons between MCI subgroups and with seven cognitively normal elderly subjects were performed using SPM2. RESULTS: At baseline aMCI and snaMCI exhibited a similar pattern of hypometabolism, mostly in the posterior cingulate gyrus, as compared with controls. In the comparison between the MCI subtypes, the aMCI subjects showed reduced metabolism in the medial temporal lobes (MTL) (hippocampus, fusiform gyrus and amygdala). At follow-up 12 aMCI developed Alzheimer's disease (AD), while snaMCI had a heterogeneous course, including five subjects who developed Lewy body dementia. CONCLUSIONS: The patterns of altered brain metabolism in aMCI and snaMCI subjects compared to controls are similar and do not provide evidence for making clinical distinctions between them. Comparison between the two MCI subtypes showed MTL hypometabolism in aMCI subjects, possibly reflecting the fact that most had prodromal AD.


Subject(s)
Amnesia/pathology , Cognition Disorders/pathology , Fluorodeoxyglucose F18/pharmacology , Hippocampus/metabolism , Positron-Emission Tomography/methods , Aged , Amnesia/diagnosis , Automation , Cognition Disorders/diagnosis , Female , Glucose/metabolism , Hippocampus/pathology , Humans , Lewy Body Disease/pathology , Male , Middle Aged , Neuropsychological Tests , Temporal Lobe/pathology
16.
Q J Nucl Med Mol Imaging ; 53(3): 281-9, 2009 Jun.
Article in English | MEDLINE | ID: mdl-18594484

ABSTRACT

AIM: Lower gastrointestinal (GI) hemorrhage is a complex clinical problem that requires disciplined evaluation for successful management. This study was conducted to evaluate the applicability of single photon emission computed tomography/computed tomography (SPECT/CT) in patients with acute lower gastrointestinal bleeding undergoing scintigraphy with 99mTc-labelled red blood cells (RBC), and to assess the additional clinical value of fused images when compared to the standard radionuclide scan. METHODS: Twenty-seven patients presenting with acute lower GI tract hemorrhage were studied with conventional dynamic and planar 99mTc-RBC imaging. In 19 patients with positive findings on scans taken within 6 hours, a SPECT/CT study was immediately performed using a hybrid system composed of a dual-head, variable angle gamma camera and an X-ray tube. The number of patients in whom SPECT/CT changed the scintigraphic interpretation with regard to the presence or site of GI blood loss as confirmed by other diagnostic or therapeutical procedures was recorded. RESULTS: Image fusion was easy and successful in all patients showing perfect correspondence between SPECT and CT data and allowing precise anatomical localization of the sites of 99mTc-RBC extravasation. SPECT/CT had significant impact on the scintigraphic results in 7/19 patients (36.8%): in 6 patients it precisely localized the bleeding foci whose location could not be identified in standard scans and in one it excluded the presence of an active GI hemorrhage. CONCLUSIONS: SPECT/CT with a hybrid system is feasible and useful for facilitating imaging interpretation and improving the accuracy of 99mTc-RBC scintigraphy in patients with acute lower GI bleeding.


Subject(s)
Erythrocytes/diagnostic imaging , Gastrointestinal Hemorrhage/diagnosis , Intestinal Diseases/diagnosis , Subtraction Technique/instrumentation , Technetium , Tomography, Emission-Computed, Single-Photon/instrumentation , Tomography, X-Ray Computed/instrumentation , Adult , Aged , Equipment Design , Equipment Failure Analysis , Female , Humans , Male , Middle Aged , Radiopharmaceuticals , Reproducibility of Results , Sensitivity and Specificity
17.
Q J Nucl Med Mol Imaging ; 51(2): 111-26, 2007 Jun.
Article in English | MEDLINE | ID: mdl-17420713

ABSTRACT

Molecular and cellular imaging is a branch of biomedical sciences that combines the use of imaging instrumentation and biotechnology to characterize molecular and cellular processes in living organisms in normal and pathologic conditions. The two merging areas of research behind molecular and cellular imaging are detection technology, i.e. scanners and imaging devices, and development of tracers, contrast agents and reporter probes that make imaging with scanners and devices possible. Several in vivo imaging instruments currently used in human studies, such as computer tomography, ultrasound, magnetic resonance, positron emission tomography and single photon emission computed tomography, have been rescaled for small animal studies, while other methods initially used for in vitro evaluation, such as bioluminescence and fluorescence, have been refined for in vivo imaging. Conventional imaging relies on the use of non specific contrast agents and classical probes; however, newly developed targeted contrast agents and activable ''smart'' imaging probes for so-called ''targeted imaging'' have demonstrated high specificity and high signal to noise ratio in small animal studies. This review focuses on basic recent findings in the technical aspects of molecular and cellular imaging modalities (equipment, targeted probe and contrast agents and applied combinations of instrumentation and probe) with particular attention to the choice of the future: the multimodal imaging approach.


Subject(s)
Cell Physiological Phenomena , Drug Delivery Systems/instrumentation , Image Enhancement/instrumentation , Molecular Probe Techniques/instrumentation , Nuclear Medicine/instrumentation , Positron-Emission Tomography/instrumentation , Tomography, Emission-Computed, Single-Photon/instrumentation , Animals , Equipment Design , Forecasting , Humans
18.
Neurol Sci ; 26(5): 358-61, 2005 Dec.
Article in English | MEDLINE | ID: mdl-16388374

ABSTRACT

Description of a case of probable dementia with Lewy bodies featuring parkinsonism, dementia and supranuclear gaze palsy. This is the first patient to our knowledge affected with vertical gaze palsy receiving clinical diagnosis of DLB when alive and to be treated with cholinesterase inhibitors.


Subject(s)
Lewy Body Disease/pathology , Supranuclear Palsy, Progressive/pathology , Aged , Diagnosis, Differential , Frontal Lobe/diagnostic imaging , Humans , Lewy Body Disease/complications , Lewy Body Disease/diagnostic imaging , Male , Neuropsychological Tests , Positron-Emission Tomography/methods , Psychiatric Status Rating Scales , Supranuclear Palsy, Progressive/complications , Supranuclear Palsy, Progressive/diagnostic imaging
19.
Ann Ig ; 16(4): 569-78, 2004.
Article in Italian | MEDLINE | ID: mdl-15366515

ABSTRACT

As a result of Italian law, DPR 15/7/2003 n. 254, about hospital waste, and given that little has been written about recycling waste glass in hospitals, a survey of 28 health departments in Lazio was performed. The objectives were: to estimate the mean quantity of clear vitreous waste in one year, to estimate how vitreous waste is administered, to estimate the extent of the use of plastic instead of glass, to analyse the costs and benefits of glass use and/or plastic use and to evaluate staff training about hospital waste disposal. The average production of clear vitreous waste was 0.28 kilogram per day per hospital bed occupied. (This would be the theoretical maximum quantity of glass to be recycled). Among the 28 departments studied, 82% separated waste products but only 36% disposed of glass in accordance with the law. The estimated possible savings on glass phleboclysis in 2002 year were 35,000 euro. Staff training could avoid this conspicuous waste of money. Fifteen departments also used plastic phleboclysis; of these, in 2 departments plastic waste is separated in the wards, but unfortunately this material is later disposed of in the bins for general solid urban waste. The other thirteen hospitals dispose of waste plastic as infectious material. Using glass phleboclysis instead of plastic phleboclysis would save about 680,000 euros per year. The disposal of glass waste material in practice was not found to follow the principles taught in the training courses. Theoretic data about glass production, estimated in this survey, refers only to clear glass and it is an underestimate of that of all glass used in departments. The quantity of glass actually recycled has been about 0.14 kilogram per day per hospital bed occupied and thus only 50% of the theoretical quantity (0.28 kilogram per day per hospital bed occupied). This percentage could be improved by effective training. Ideally, the disposal of waste glass would follow the legal requirements and be monitored locally.


Subject(s)
Glass , Refuse Disposal/standards , Data Collection , Italy , Refuse Disposal/statistics & numerical data
20.
Q J Nucl Med Mol Imaging ; 48(2): 76-81, 2004 Jun.
Article in English | MEDLINE | ID: mdl-15243405

ABSTRACT

Although any patient with a suspected brain tumor, either primary or metastatic, should be studied with anatomic imaging modalities such as angiography, computerized tomagraphy (CT) or magnetic resonance imaging (MRI), nuclear medicine techniques are available to further characterize some biological features of brain lesions and help in diagnosis and therapy planning. Bloob-brain-barrier disruption can be easily assessed with single-photon emission tomography (SPET), whereas focal metabolic changes can be better demonstrated by positron emission tomography (PET) as specific radiopharmaceuticals are available to detect changes in glucose utilization and aminoacid uptake with this technique. Expression of specific tumoral antigens is the basis of imaging with radioimmunoscintigraphy, a promising technique that can be applied to brain tumor therapy. The major clinical applications of nuclear medicine in the study of brain tumors -- evaluation of the extension of a tumoral mass, differential diagnosis and evaluation of therapy and prognosis -- are discussed.


Subject(s)
Brain Neoplasms/diagnostic imaging , Tomography, Emission-Computed, Single-Photon , Tomography, Emission-Computed , Brain Neoplasms/diagnosis , Brain Neoplasms/metabolism , Glucose/metabolism , Humans , Radioimmunodetection
SELECTION OF CITATIONS
SEARCH DETAIL
...